博瑞医药
(688166)
| 流通市值：134.77亿 | | | 总市值：134.77亿 |
| 流通股本：4.22亿 | | | 总股本：4.22亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 976,825,695.67 | 657,688,446.99 | 340,133,145.78 | 1,179,517,532.47 |
| 营业收入 | 976,825,695.67 | 657,688,446.99 | 340,133,145.78 | 1,179,517,532.47 |
| 二、营业总成本 | 798,339,394.77 | 554,212,734.85 | 267,341,183.31 | 980,322,905.2 |
| 营业成本 | 410,241,469.76 | 294,016,999.7 | 145,694,074.37 | 521,413,987.89 |
| 税金及附加 | 5,066,165.95 | 3,149,122.03 | 1,575,568.42 | 5,711,837.01 |
| 销售费用 | 56,240,619.67 | 39,640,646.11 | 14,811,867.65 | 64,069,015.18 |
| 管理费用 | 84,725,762.7 | 55,778,382.34 | 28,542,267.17 | 116,395,385.47 |
| 研发费用 | 212,379,034.01 | 142,763,374.89 | 65,047,828.56 | 248,592,240.65 |
| 财务费用 | 29,686,342.68 | 18,864,209.78 | 11,669,577.14 | 24,140,439 |
| 其中:利息费用 | 39,583,215.14 | 27,568,677.41 | 13,914,465.29 | 44,424,247.1 |
| 其中:利息收入 | 8,787,032.44 | 7,014,494.12 | 1,537,804.55 | 17,991,271.98 |
| 加:公允价值变动收益 | 1,009,679.56 | -1,564,027.29 | -2,480,193.14 | -520,009.36 |
| 加:投资收益 | -9,634,825.62 | -6,584,076.76 | -4,545,946.74 | -14,741,061.07 |
| 资产减值损失(新) | -5,233,377.22 | -5,233,377.22 | - | -21,489,955.18 |
| 信用减值损失(新) | -7,251,559.45 | -4,417,727.49 | 125,751.14 | -2,467,297.19 |
| 其他收益 | 10,974,695.35 | 8,720,734.45 | 4,800,153.8 | 30,268,073.7 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 168,350,913.52 | 94,397,237.83 | 70,691,727.53 | 190,244,378.17 |
| 加:营业外收入 | 35,088.06 | 28,588.06 | 6,317.72 | 199,016.67 |
| 减:营业外支出 | 309,658.44 | 119,565.61 | 111,082.3 | 1,673,334.93 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 168,076,343.14 | 94,306,260.28 | 70,586,962.95 | 188,770,059.91 |
| 减:所得税费用 | 21,318,816.3 | 12,079,271.64 | 8,777,130.59 | 15,346,423.13 |
| 六、净利润 | 146,757,526.84 | 82,226,988.64 | 61,809,832.36 | 173,423,636.78 |
| 持续经营净利润 | 146,757,526.84 | 82,226,988.64 | 61,809,832.36 | 173,423,636.78 |
| 归属于母公司股东的净利润 | 177,408,752.96 | 106,364,734.26 | 64,069,918.71 | 202,466,024.77 |
| 少数股东损益 | -30,651,226.12 | -24,137,745.62 | -2,260,086.35 | -29,042,387.99 |
| (一)基本每股收益 | 0.42 | 0.25 | 0.15 | 0.48 |
| (二)稀释每股收益 | 0.42 | 0.25 | 0.15 | 0.48 |
| 八、其他综合收益 | -35,070,709.12 | -35,136,666.18 | -2,285,122.48 | -26,399,481.11 |
| 归属于母公司股东的其他综合收益 | -35,070,709.12 | -35,136,666.18 | -2,285,122.48 | -26,399,481.11 |
| 九、综合收益总额 | 111,686,817.72 | 47,090,322.46 | 59,524,709.88 | 147,024,155.67 |
| 归属于母公司股东的综合收益总额 | 142,338,043.84 | 71,228,068.08 | 61,784,796.23 | 176,066,543.66 |
| 归属于少数股东的综合收益总额 | -30,651,226.12 | -24,137,745.62 | -2,260,086.35 | -29,042,387.99 |
| 公告日期 | 2024-10-30 | 2024-08-24 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |